WEST HAVEN, Conn. & SAN FRANCISCO--(BUSINESS WIRE)--Cellinfinity Bio, a privately held pioneer biotechnology company developing first/best-in-class cell therapy products against solid tumors and other ...
– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results